Suppr超能文献

一名青少年患者的单中心Castleman病在接受利妥昔单抗-CHOP化疗或放射治疗后复发。

Unicentric Castleman disease relapsed after rituximab-CHOP chemotherapy or radiation therapy in an adolescent.

作者信息

Baek Hee Jo, Kook Hoon, Han Dong Kyun, Shin Myung-Geun, Kim Hyoung Seok, Hwang Tai Ju

机构信息

Department of Pediatrics, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, Korea.

出版信息

J Pediatr Hematol Oncol. 2012 Jul;34(5):e206-8. doi: 10.1097/MPH.0b013e3182352dc7.

Abstract

Castleman disease (CD), an atypical lymphoproliferative disorder of unknown etiology, is rare. Unicentric CD can be cured after resection of the involved lymph nodes. However, rarely, patients with the unicentric-plasma cell variant may require additional therapy after resection for persistent systemic symptoms. The clinical course of such patients has not been well characterized. We report the case with relapsed unicentric-plasma cell variant CD who was eventually treated with complete surgical resection. This patient had no response to combination chemotherapy with rituximab after incomplete resection and no response to radiation after relapse.

摘要

卡斯特尔曼病(CD)是一种病因不明的非典型淋巴增殖性疾病,较为罕见。单中心型CD在切除受累淋巴结后可治愈。然而,极少数单中心浆细胞型患者在切除术后可能因持续性全身症状而需要额外治疗。这类患者的临床病程尚未得到充分描述。我们报告了一例复发的单中心浆细胞型CD患者,最终通过完整手术切除得到治疗。该患者在不完全切除后对利妥昔单抗联合化疗无反应,复发后对放疗也无反应。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验